The current financial score of Lexaria Bioscience Corp is 6.73. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 47.45%.
The current valuation score of Lexaria Bioscience Corp is 7.50. Its current P/E ratio is -6.80, which is -91.26% below the recent high of -0.59 and -336.73% above the recent low of -29.68.
The current earnings forecast score of Lexaria Bioscience Corp is 8.00. The average price target is 52.50, with a high of 82.50 and a low of 22.50.
The current price momentum score of Lexaria Bioscience Corp is 8.56. Currently, the stock price is trading between the resistance level at 10.81 and the support level at -0.76, making it suitable for range-bound swing trading.
The current institutional shareholding score of Lexaria Bioscience Corp is 3.00. The latest institutional shareholding proportion is 6.61%, representing a quarter-over-quarter decrease of 22.09%.
The current risk assessment score of Lexaria Bioscience Corp is 1.22. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.